‘Next Big Thing Report’ Highlights Estimated 45 Million Addressable Market for Galmed’s (“GLMD”) Aramchol™ Treatment of NASH Liver Disease

 

NORTH BETHESDA, MD, Sep 28, 2015 – NextBigThingInvestor.com released an interview by Tobin Smith, CEO of NBT Equities Research and former Contributor/Guest Anchor for Fox News & Fox Business News with Josh Blacher, CFO of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD).

 

“During the ‘The Next Big Thing Report’ segment, Mr. Smith refers to Aramchol™ as a potential blockbuster treatment for the growing medical concern of fatty liver disease, including NASH, alongside other metabolic disorders including obesity, high cholesterol, high blood pressure, and adult diabetes. NASH is now estimated to affect about 45 million adults in the US and EU-5 alone,” said Galmed’s CFO, Josh Blacher.

 

“Aramchol™ is designed to root out the core problem of NASH, excess liver fat. Galmed’s clinical studies to date have demonstrated that Aramchol-treated patients reduced liver fat by 20 percent compared to untreated patients and improved important cardiovascular markers. In its 4 clinical trials to date, Aramchol™ also has not shown observable adverse side effects.”

 

Mr. Blacher concluded, “With no treatment for NASH patients currently available, our larger Phase IIb clinical trial — the ARREST Study — will test up to 2X higher dosages with hopes of an even better therapeutic effect and similar safety results. Additional exposure from Mr. Smith and the financial community is a key component to our success.”

 

Mr. Smith commented, “Assuming launch in 2020, recent published equity research indicates up to $3 billion a year peak market sales for Aramchol by 2024.”

 

Mr. Smith noted, “The underreported worldwide NASH liver disease epidemic is highly correlated to other metabolic-related disorders that continue to grow at alarming rates, such as elevated levels of LDL cholesterol and Type 2 diabetes worldwide. Without an effective treatment, the end-stage outlook for NASH patients is an increased risk of a life-threatening cardiovascular event (heart attack or stroke) or eventually liver transplantation, which is not only prohibitively expensive but impractical given transplantable liver availability.”

 

The two part video interview with Tobin Smith can be accessed on the following links:
Part I: https://nbtequitygroup.wistia.com/medias/tmp49znkx3
Part II: https://nbtequitygroup.wistia.com/medias/32qbqxwatw

 

NextBigThingInvestor.com is a division of Velocity Studio LLC focused on transformational growth industries and companies. The company was founded by well-known equities research analyst Tobin Smith, a former contributing market analyst (2000-2013) for Fox News Channel and a regular panelist on its highly rated “Bulls & Bears” weekly business program. Mr. Smith is the Editor-in-Chief of NBT Investor Pro, an investment newsletter advisory focused on investments in transformational change.

 

About Galmed Pharmaceuticals, Ltd.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of liver diseases. It is developing Aramchol, which is in Phase IIb clinical trial for the treatment of non-alcoholic steato-hepatitis in patients who also suffer from obesity and insulin resistance. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

 

More information about Galmed Pharmaceuticals can be found at http://galmedpharma.com.

 

A CommPro Worldwide PR Event

 

Contacts:

 

PR & Media Contact:

Matt Bird, CEO
CommPro Worldwide

C: +1 (646) 401-4499
E: matt.bird@commpro.com